We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

HIV/STD Safer Sex Skills Groups for Men in Drug Treatment Programs - 1

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: June 9, 2004
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Drug Abuse (NIDA)
The purpose of this study is to evaluate a five-session Human Immunodeficiency Virus/Acquired Immune Deficiency Disease (HIV/AIDS) group therapy designed specifically for heterosexual men. This therapy is compared to standard HIV/AIDS education, which generally consists of a single session of HIV education.

Condition Intervention Phase
Behavior Therapy Behavioral: Behavior Therapy Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: HIV/STD Safer Sex Skills Groups for Men in Drug Treatment Programs

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • AIDS risk behavior

Estimated Enrollment: 630
Study Start Date: April 2004
Study Completion Date: September 2005
Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
All adult males age 18 and above in drug abuse treatment at participating Community Treatment Providers will be invited to participate.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00084175

United States, California
Matrix Institute on Addictions
Rancho Cucamonga, California, United States, 91730
San Francisco General Hospital
San Francisco, California, United States, 94110
United States, Connecticut
Hartford Dispensary
New Britain, Connecticut, United States, 06051
CT Renaissance, Inc.
Norwalk, Connecticut, United States, 06852
United States, New Mexico
Life Link
Santa Fe, New Mexico, United States, 87505
United States, New York
Staten Island University Hospital
Staten Island, New York, United States, 10309
United States, North Carolina
Addiction Drug Services-Highpoint
High Point, North Carolina, United States, 27265
South Light
Raleigh, North Carolina, United States, 27604
United States, Ohio
Comprehensive Addiction Services System
Toledo, Ohio, United States, 43620
United States, Pennsylvania
The Consortium
Philadelphia, Pennsylvania, United States, 19104
Thomas Jefferson Intensive Sub. Abuse TP
Philadelphia, Pennsylvania, United States, 19107
United States, South Carolina
LRADAC-Lexington-Richmond Alcohol & Drug Council
Columbia, South Carolina, United States, 29204
United States, Washington
Evergreen Treatment Services
Seattle, Washington, United States, 98134 1618
United States, West Virginia
Prestera Center for Mental Health Svcs.
Huntington, West Virginia, United States, 25704
Sponsors and Collaborators
University of Washington
Principal Investigator: Donald Calsyn, Ph.D. University of Washington